Aurochem Pharmaceuticals (india) Privatelimited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aurochem Pharmaceuticals (india) Privatelimited Pharmaceutical Export Portfolio Dataset — 3 Products, $715.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aurochem Pharmaceuticals (india) Privatelimited — Pharmaceutical Exporter Profile (2026) | 3 Products, $715.4K Trade | TransData Nexus

Aurochem Pharmaceuticals (india) Privatelimited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $715.4K Total Trade · DGFT Verified

Aurochem Pharmaceuticals (india) Privatelimited is an Indian pharmaceutical exporter with a total trade value of $715.4K across 3 products in 2 therapeutic categories. Based on 46 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Chondroitin ($277.1K), Glucosamine ($223.3K), Ornidazole ($215.0K).

Aurochem Pharmaceuticals (india) Privatelimited — Export Portfolio & Destination Treemap

Aurochem Pharmaceuticals (india) Privatelimited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aurochem Pharmaceuticals (india) Privatelimited? — Company Overview & Market Position

Aurochem Pharmaceuticals (India) Private Limited, established on November 21, 1994, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH1994PTC083100. As of the latest available data, Aurochem Pharmaceuticals has an authorized share capital of ₹2,500,000 and a paid-up capital of ₹1,526,000. The company employs between 11 to 50 individuals, reflecting its mid-sized operational scale. Aurochem Pharmaceuticals specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily focusing on nutritional supplements and advanced antibiotics.

What Does Aurochem Pharmaceuticals (india) Privatelimited Export? — Product Portfolio Analysis

Top Products by Export Value

1Chondroitin$277.1K 2Glucosamine$223.3K

Product Portfolio — Top 3 by Export Value

Aurochem Pharmaceuticals (india) Privatelimited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Chondroitin	Nutritional Supplements	$277.1K	19	5.5%	6
2	Glucosamine	Nutritional Supplements	$223.3K	12	1.7%	14
3	Ornidazole	Advanced Antibiotics	$215.0K	15	1.2%	10

Aurochem Pharmaceuticals (india) Privatelimited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $715.4K. The top category is Nutritional Supplements (69.9% of portfolio), followed by Advanced Antibiotics (30.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aurochem Pharmaceuticals (india) Privatelimited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Aurochem Pharmaceuticals operates manufacturing facilities in Mumbai and Palghar, Maharashtra. The Mumbai facility is located at 334, 3rd Floor, Gundecha Industrial Complex, Akurli Road, Kandivali East, Mumbai, Maharashtra 400101. The Palghar facility is situated at 58, Boisar - Palghar Road, Palghar West, Palghar Taluka Industrial Co-operative Estate, Palghar, Maharashtra 401404. Both facilities are WHO-GMP certified, ensuring compliance with international manufacturing standards. These plants are equipped to produce a range of pharmaceutical products, with a particular emphasis on nutritional supplements and advanced antibiotics.

3Key Leadership

The leadership team at Aurochem Pharmaceuticals comprises several key individuals:

Pravinchandra Bhikhabhai Desai: Director since November 21, 1994.

Piyush Mansukhlal Shah: Director since November 21, 1994.

Pallav Mahesh Shah: Director since April 1, 2015.

Himanshu Pravin Desai: Director since February 8, 2014.

These individuals have been instrumental in steering the company's strategic direction and operational growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aurochem Pharmaceuticals (india) Privatelimited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aurochem Pharmaceuticals has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold WHO-GMP certifications, which are recognized by regulatory authorities in these regions. This certification facilitates the export of their pharmaceutical products to these markets. While specific regulatory filings and approvals in each country are not detailed in the available sources, the WHO-GMP certification indicates a commitment to maintaining high manufacturing standards, aligning with the requirements of these regulated markets.

2Emerging Markets

Aurochem Pharmaceuticals has expanded its reach into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The WHO-GMP certification of their manufacturing facilities enables the company to access these markets, as it is a prerequisite for many countries in these regions to import pharmaceutical products. This strategic move allows Aurochem Pharmaceuticals to tap into growing healthcare needs and establish a broader global footprint.

3Geographic Strategy

Aurochem Pharmaceuticals (india) Privatelimited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Aurochem Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available in the provided sources. However, the company's WHO-GMP certification suggests adherence to international manufacturing standards, which is a critical factor for FDA approval processes. To obtain precise information on FDA-related approvals and inspections, direct communication with the company or the FDA would be necessary.

2WHO & EU GMP

Aurochem Pharmaceuticals' manufacturing facilities are WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification is recognized by the European Union and is essential for exporting pharmaceutical products to EU member countries. The WHO-GMP certification underscores the company's commitment to maintaining high manufacturing standards, ensuring product quality and safety in international markets.

3CDSCO & Indian Regulatory

Aurochem Pharmaceuticals (india) Privatelimited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Aurochem Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific competitors in overlapping categories are not detailed in the available sources, the company's focus on nutritional supplements and advanced antibiotics positions it in markets with significant competition. The WHO-GMP certification and the company's export activities indicate a competitive edge in meeting international standards and accessing global markets.

2Key Differentiators

Aurochem Pharmaceuticals' key differentiators include its WHO-GMP certified manufacturing facilities, which ensure adherence to international quality standards. The company's focus on finished pharmaceutical formulations, particularly in the areas of nutritional supplements and advanced antibiotics, allows it to cater to specific market needs. Additionally, the company's strategic expansion into emerging markets demonstrates its adaptability and commitment to global growth.

3Strategic Position

Aurochem Pharmaceuticals' current strategic direction emphasizes the production and export of finished pharmaceutical formulations, with a particular focus on nutritional supplements and advanced antibiotics. The company's WHO-GMP certification supports its ability to meet international manufacturing standards, facilitating access to regulated markets. Looking ahead, Aurochem Pharmaceuticals may consider expanding its product portfolio to include generics, specialty drugs, biosimilars, or contract development and manufacturing organization (CDMO) services to further enhance its market position and growth prospects.

Buyer Due Diligence Brief — Evaluating Aurochem Pharmaceuticals (india) Privatelimited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Aurochem Pharmaceuticals has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $715,000 USD across 46 shipments from 2022 to 2026. The company's portfolio is concentrated, with its top three products—Chondroitin, Glucosamine, and Ornidazole—accounting for 100% of its exports. This concentration indicates a focused product strategy, which can be advantageous in maintaining quality and expertise in specific therapeutic areas. The WHO-GMP certification of its manufacturing facilities further underscores the company's commitment to quality and reliability in its export operations.

2Certifications to Verify

Importers should verify the following certifications when considering Aurochem Pharmaceuticals as a supplier:

WHO-GMP Certification: This certification ensures that the manufacturing facilities adhere to the World Health Organization's Good Manufacturing Practices, indicating compliance with international quality standards.

EU GMP Certification: This certification confirms that the manufacturing processes meet the European Union's Good Manufacturing Practices, which is essential for exporting pharmaceutical products to EU member countries.

Frequently Asked Questions — Aurochem Pharmaceuticals (india) Privatelimited

How many pharmaceutical products does Aurochem Pharmaceuticals (india) Privatelimited export from India?

Aurochem Pharmaceuticals (india) Privatelimited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Chondroitin ($277.1K), Glucosamine ($223.3K), Ornidazole ($215.0K). Total export value is $715.4K.

What is Aurochem Pharmaceuticals (india) Privatelimited's total pharmaceutical export value?

Aurochem Pharmaceuticals (india) Privatelimited's total pharmaceutical export value is $715.4K, based on 46 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aurochem Pharmaceuticals (india) Privatelimited cover?

Aurochem Pharmaceuticals (india) Privatelimited exports across 2 therapeutic categories. The largest are Nutritional Supplements (69.9%, 2 products), Advanced Antibiotics (30.1%, 1 products).

Get Full Aurochem Pharmaceuticals (india) Privatelimited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.